Schroder Investment Management Group Boosts Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Schroder Investment Management Group raised its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 67.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 109,849 shares of the company’s stock after purchasing an additional 44,310 shares during the period. Schroder Investment Management Group owned 0.22% of Immunocore worth $3,447,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in Immunocore in the 2nd quarter worth about $1,621,000. Acadian Asset Management LLC lifted its holdings in Immunocore by 392.3% during the second quarter. Acadian Asset Management LLC now owns 90,798 shares of the company’s stock valued at $2,843,000 after purchasing an additional 72,355 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new position in Immunocore during the second quarter worth about $292,000. Banque Transatlantique SA bought a new position in Immunocore during the first quarter worth about $278,000. Finally, Checkpoint Capital L.P. purchased a new position in shares of Immunocore in the first quarter worth about $267,000. 84.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They set a “neutral” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, October 22nd. Morgan Stanley lifted their price target on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Finally, Wells Fargo & Company initiated coverage on Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.00.

Insider Buying and Selling at Immunocore

In related news, insider David M. Berman sold 22,532 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.40% of the company’s stock.

Immunocore Trading Down 3.6%

Shares of IMCR stock opened at $38.78 on Friday. The company has a market capitalization of $1.96 billion, a PE ratio of -68.04 and a beta of 0.77. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $23.15 and a 52-week high of $40.71. The business’s fifty day moving average is $35.15 and its 200 day moving average is $34.28. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. The business had revenue of $103.69 million for the quarter, compared to analyst estimates of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The company’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. On average, equities research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.